These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 5786222)

  • 1. Dr. Goddard and the PMA.
    Rev Allergy; 1969 Mar; 23(3):161-3. PubMed ID: 5786222
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical costs and the drug industry.
    Schwartz H
    Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical costs and the drug industry.
    Schwartz H
    Med Times; 1981 Mar; 109(3):21s-24s, 28s. PubMed ID: 7207081
    [No Abstract]   [Full Text] [Related]  

  • 4. Food and Drug Administration. Tempest over polio vaccine.
    Anderson C
    Nature; 1991 Jun; 351(6327):510. PubMed ID: 2046758
    [No Abstract]   [Full Text] [Related]  

  • 5. What does R&D really cost?
    Huff B
    GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
    [No Abstract]   [Full Text] [Related]  

  • 6. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 7. Who pays what in drug development.
    Love J
    Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
    [No Abstract]   [Full Text] [Related]  

  • 8. Costs of submitting an IND and obtaining an effective NDA for a new oral drug.
    Elvers WB
    Pharmacol Ther Dent; 1971 Feb; 1(2):102-10. PubMed ID: 5293558
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs drive acceptance of transgenic bioassays.
    Swan N
    Nat Biotechnol; 1998 Oct; 16(10):902-3. PubMed ID: 9788336
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Now it's their turn'.
    Silverman M
    J Am Pharm Assoc; 1971 Jul; 11(7):374-5 passim. PubMed ID: 5142131
    [No Abstract]   [Full Text] [Related]  

  • 11. Herbal Rx: the promises and pitfalls.
    Consum Rep; 1999 Mar; 64(3):44-8. PubMed ID: 10557627
    [No Abstract]   [Full Text] [Related]  

  • 12. Can "phase IV" trials work for you?
    Borfitz D
    Med Econ; 2003 Jun; 80(11):58, 64, 67. PubMed ID: 12828120
    [No Abstract]   [Full Text] [Related]  

  • 13. Dr. Goddard: firm hand on drug safety.
    Foster JT
    Mod Hosp; 1966 Nov; 107(5):99-100. PubMed ID: 5978522
    [No Abstract]   [Full Text] [Related]  

  • 14. An interview with Dr. James L. Goddard.
    Callahan B
    Hosp Prog; 1967 Sep; 48(9):62-6. PubMed ID: 6073602
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NARD and Dr. Goddard.
    Provost GP
    Am J Hosp Pharm; 1968 Feb; 25(2):59. PubMed ID: 5643645
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech and pharma face more costly clinical trials.
    Brower V
    Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical research: outlook from industry.
    Echols R
    Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
    [No Abstract]   [Full Text] [Related]  

  • 19. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of change.
    Munns WA
    IMS Ind Med Surg; 1968 Jun; 37(6):450-3. PubMed ID: 5243197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.